A program called iPledge was designed to ensure that every user of Accutane or its generic competitors — and every doctor who prescribes it and every pharmacy that sells it — follows strict rules to make sure that women don't get pregnant while on the drug. Among those rules are month-by-month prescriptions based on passing pregnancy tests.
But last summer, the Food and Drug Administration heard evidence that iPledge hasn't ended the problem: There were 122 pregnancies in the program's first year and another 37 in the four months since. Another 19 pregnancies occurred in women who managed to get the drug despite never enrolling in iPledge.
Still, in October the FDA agreed to a few changes to the program, and announced Wednesday that iPledge is now implementing these changes:
_Women of childbearing age who don't fill a prescription within seven days of a pregnancy test will be allowed to get another test and then fill the prescription — with the exception of the initial prescription. Until now, those who didn't act within seven days were frozen out of the program for the next 23 days.
_Those women will have to fill the prescription within seven days of a pregnancy test rather than within seven days of first seeing their doctor.
Hot on the heels of the resounding success of iPledge, the $100 million program intended to insure that Accutane users don't get pregnant while on the drug, the FDA has decided to ease restrictions on access to the drug: